Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer’s Disease from 2004 to 2022

Abstract

<b><i>Introduction:</i></b> Stem cell-based regenerative medicine has provided an excellent opportunity to investigate therapeutic strategies and innovative treatments for Alzheimer’s disease (AD). However, there is an absence of visual overviews to assess the published literature systematically. <b><i>Methods:</i></b> In this review, the bibliometric approach was used to estimate the searched data on stem cell research in AD from 2004 to 2022, and we also utilized CiteSpace and VOSviewer software to evaluate the contributions and co-occurrence relationships of different countries/regions, institutes, journals, and authors as well as to discover research hot spots and encouraging future trends in this field. <b><i>Results:</i></b> From 2004 to 2022, a total of 3,428 publications were retrieved. The number of publications and citations on stem cell research in AD has increased dramatically in the last nearly 20 years, especially since 2016. North America and Asia were the top 2 highest output regions. The leading country in terms of publications and access to collaborative networks was the USA. Centrality analysis revealed that the UCL (0.05) was at the core of the network. The Journal of Alzheimer’s Disease (<i>n</i> = 102, 2.98%) was the most productive academic journal. The analyses of keyword burst detection indicated that exosomes, risk factors, and drug delivery only had burst recently. Citations and co-citation achievements clarified that cluster #0 induced pluripotent stem cells, #2 mesenchymal stem cells, #3 microglia, and #6 adult hippocampal neurogenesis persisted to recent time. <b><i>Conclusion:</i></b> This bibliometric analysis provides a comprehensive guide for clinicians and scholars working in this field. These analysis and results hope to provide useful information and references for future understanding of the challenges behind translating underlying stem cell biology into novel clinical therapeutic potential in AD.

Hydrogel nanoparticles as new drug delivery system for CNS disorders

“…TBI treatment has a lot of promise with this [115] . Stem cell replacement therapy with injectable hydrogels for transplanted stem cells has tremendous potential in TBI therapy [116] . Wang et al.…”

Cognitive Impairment in Multiple Sclerosis

“…These processes related to ROS, mitochondrial injury, the shortening of TLs, and cell senescence can hasten aging, and also promote the onset of neurodegenerative disorders such as dementia and Alzheimer's disease (AD) [55,58,67,69,71,73,95]. Individuals with shorter leukocyte TL lengths can have an increased risk of dementia and AD [56].…”

“…If one considers disorders such as AD, familial cases of AD (FAD) affect a much smaller proportion of the population. FAD is an autosomal dominant form of a mutated amyloid precursor protein (APP) gene, and occurs in approximately 200 families worldwide [71,95,[98][99][100][101][102]. FAD occurs most often prior to age 55, and results from variable single-gene mutations on chromosomes 1, 14, and 21 [23,103,104].…”

“…As age and lifespan increases in the population, it is expected that the number of individuals with AD will increase to 30 million individuals over the next 15 to 20 years [69,105,113]. At present, fifty million people in the world, or five percent of the global population, have dementia [24,31,73,95,98,106,108,114]. When one considers the year 2030, 82 million people will endure disability from cognitive loss.…”

Research on therapeutic clinical trials including immunotherapy in Triple- negative Breast cancer: A bibliometric analysis

“…is the reason for the popularity of bibliometric analysis 7 . Thus, it has been used in various areas such as cardiovascular diseases 8 , Alzheimer's Disease 9 ,diabetes 10 and so on, becoming progressively more signi cant in evaluating hotspots and developing clinical trial procedures about TNBC treatment.…”